cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Merrimack Pharmaceuticals Inc
4 own
28 watching
Current Price
$12.65
$-0.18
(-1.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
182.88M
52-Week High
52-Week High
13.15000
52-Week Low
52-Week Low
10.10000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
0.275787
P/E Ratio
P/E Ratio
63.9578
iconMarket Capitalization182.88M
icon52-Week High13.15000
icon52-Week Low10.10000
iconAverage Volume0.05M
iconDividend Yield0.275787
iconP/E Ratio63.9578
What does the Merrimack Pharmaceuticals Inc do?
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. It offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The company's therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trial for treating patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trial for the treatment of glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trial for treating metastatic breast cancer. Its therapeutic oncology candidates also include MM-302 for treating patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, the company's therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; MM-151 that has completed a Phase I clinical trial for treating solid tumors; and MM-310 for treating solid tumors. Further, it is developing preclinical product candidates for solid tumor indications. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Merrimack Pharmaceuticals Inc make?
News & Events about Merrimack Pharmaceuticals Inc.
Zolmax
10 months ago
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK Get Rating) Director Noah G. Levy purchased 100,000 shares of the businesss stock in a transaction that occurred on Thursday, January 12th. The shares were bought at an average price of $11.90 per share, for a total transaction of $1,190,000.00. Following...
Business Wire
1 year ago
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the Company or Merrimack), announced today that its Board of Directors (the Board) has extended the Section 382 net operating loss rights plan (the Plan) that was adopted in 2019. The Plan is designed to protect the Companys ability to use its...
PR Newswire
1 year ago
Thinking about buying stock in Merrimack Pharmaceuticals, Roblox, Mullen Automotive, Plug Power, or Yamana Gold? Thinking about buying stock in Merrimack Pharmaceuticals, Roblox, Mullen Automotive, Plug Power, or Yamana Gold? PR Newswire NEW YORK, Nov. 9, 2022 NEW YORK, Nov. 9, 2022 /PRNewswire...
Ticker Report
1 year ago
StockNews.com started coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK Get Rating) in a research note issued to investors on Friday. The brokerage issued a sell rating on the biopharmaceutical companys stock. Merrimack Pharmaceuticals Stock Performance MACK opened at $4.16...
Zolmax
1 year ago
StockNews.com started coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biopharmaceutical companys stock. Merrimack Pharmaceuticals Price Performance Shares of NASDAQ:MACK opened at $4.10 on Thursday...
Frequently Asked Questions
Frequently Asked Questions
What is Merrimack Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Merrimack Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Merrimack Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Merrimack Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Merrimack Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Merrimack Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Merrimack Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Merrimack Pharmaceuticals Inc?
plus_minus_icon
What percentage is Merrimack Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Merrimack Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$12.65
$-0.18
(-1.4%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.56
$-0.00 (-0.46 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$1.50
$-0.07 (-4.17 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$5.95
$-0.04 (-0.67 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$1.46
$0.05 (3.55 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc
$0.56
$-0.00 (-0.46 %)
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
$1.50
$-0.07 (-4.17 %)
Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals Inc.
$5.95
$-0.04 (-0.67 %)
CytomX Therapeutics Inc
CytomX Therapeutics Inc
$1.46
$0.05 (3.55 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00